Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 4:10 PM ET
Seres Therapeutics Inc (MCRB) Statistics
Seres Therapeutics (MCRB) has a market cap of $14.27M. It kept -2209.55% of revenue as net income over the last 12 months. It holds $17.53M more cash than debt, 122.81% of its market cap.
Total Valuation
| Market Cap | $14.27M |
|---|---|
| Latest price (Nov 17, 2026) | $1.41 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.6x and 0.7x. Its year-end P/S ranged from 5.2x to 670.5x from 2016 to 2023.
| P/S Ratio | 6.6x |
|---|---|
| Forward P/S | 7.1x |
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 91.54% over 52 weeks and trades 49.46% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -91.54% |
| 1-Month Change | -41.74% |
| 3-Month Change | -69.87% |
| 6-Month Change | -81.05% |
| 5-Year Change | -98.54% |
| 10-Year Change | -99.18% |
| Total Return (1Y) | -91.54% |
| Total Return (3Y CAGR) | -63.24% |
| Total Return (5Y CAGR) | -61.83% |
| Return vs SPY (1Y) | -105.85% |
| Max Drawdown (1Y) | -95.11% |
| Max Drawdown (3Y) | -95.51% |
| Sharpe Ratio (1Y) | -3.10 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $2.79 |
| 200-Day Average | $6.29 |
| 52-Week Range | $1.30 to $29.98 |
| RSI (14 Days) | 23.4 |
| Average Volume (20 Days) | 97.89K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.65x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.65x |
|---|---|
| Quick Ratio | 1.65x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -219.83% and return on assets is -71.26% over the last 12 months.
| Return on Equity (ROE) | -219.83% |
|---|---|
| Return on Assets (ROA) | -71.26% |
| ROA (5Y Average) | -23.54% |
| Asset Turnover | 0.02x |
| Receivables Turnover | 9.30x |
Scores
MCRB has an Altman Z-Score of -23.27, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -23.27 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.13M over the last 12 months is down 66.32% from the 12 months before.
| Revenue | $2.13M |
|---|---|
| Revenue Growth (YoY) | -66.32% |
| Gross Profit | $2.13M |
| Operating Income | -$77.71M |
| Pretax Income | -$46.95M |
| Net Income | -$46.95M |
| EBITDA | -$45.16M |
| Reported EPS (TTM) | -$6.40 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 32.42% of the $65.89M in total assets.
| Cash and Equivalents | $17.53M |
|---|---|
| Total Debt | $0 |
| Net Cash | $17.53M |
| Net Cash Per Share | $1.76 |
| Working Capital | $13.53M |
| Shareholder Equity | $21.36M |
| Book Value Per Share | $2.14 |
| Total Assets | $65.89M |
| Total Liabilities | $44.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$63.94M |
|---|---|
| FCF Per Share | -$6.37 |
| Depreciation and Amortization | $2.89M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -3656.89%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -3656.89% |
| Pretax Margin | -2209.55% |
| Net Margin | -2209.55% |
| EBITDA Margin | -2125.36% |
Dividends and Yields
MCRB does not pay a dividend.
| Buyback Yield | -107.04% |
|---|---|
| Shareholder Yield | -107.04% |
Stock Splits
The last split was a 1-for-20 reverse split on Apr 22, 2025.
| Last Split Date | Apr 22, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 6 similar companies, MCRB has the 5th highest P/S.
P/S RatioPeer median 11.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -18.75%
| P/S Ratio | 6.6x vs 11.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -66.32% vs -18.75% median |
Analyst Forecast
Consensus estimates put revenue growth at -26.87% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -26.87% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MCRB
What is MCRB's market cap?
Seres Therapeutics has a market cap of $14.27M.
How many shares of MCRB are outstanding?
Seres Therapeutics has 9.98M shares outstanding. The count is up 13.97% from a year earlier.
Does MCRB pay a dividend?
No. Seres Therapeutics does not pay a dividend.
How much debt does MCRB have?
Seres Therapeutics has $0 of total debt and $17.53M of cash and equivalents, a net cash position of $17.53M.
MCRB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors